STYLAGE® LIPS PLUS BI-FLEX® with Lidocaine

STYLAGE® LIPS PLUS BI-FLEX® with Lidocaine — Injectable HA Lips Filler for Lip Augmentation & Perioral Volume Restoration

Product Specifications

• Drug Class: Injectable HA filler for lip augmentation (cross-linked, BI-FLEX® syringe system, with lidocaine)
• Active Ingredients: Hyaluronic acid (cross-linked) 20mg/mL; Lidocaine 0.3%; Mannitol 0.3%
• Manufacturer: Laboratories VIVACY
• Brand: STYLAGE®
• Country of Origin: France
• Strength: 20mg/mL HA; 0.3% Lidocaine; 0.3% Mannitol
• Dosage Form: Injectable gel — 1 × 1mL prefilled syringe + 2 × 30G ½ needles
• FDA Status: Not currently approved by the US FDA
• Regulatory Status: CE-marked (EU)

Mechanism of Action

STYLAGE® LIPS PLUS BI-FLEX® with Lidocaine works by integrating cross-linked HA into lip tissue, where it binds water to produce an immediate volumizing, hydrating, and defining effect at the injection site. Cross-linking slows enzymatic breakdown, extending the filler’s longevity, and the product remains fully reversible with hyaluronidase if clinical reversal is needed.

IPN-Like Technology™ distinguishes this Stylage filler from conventional single-network products. This architecture, in which two interlocked HA polymer networks share the same gel matrix, delivers superior cohesivity and resistance to mechanical deformation, both of which are particularly relevant in a treatment area that moves as constantly as the lips.

The specialized rheological profile builds on this foundation by tuning the gel’s softness, elasticity, and flow specifically to mucosal lip tissue, delivered via the high-precision BI-FLEX® syringe system, so results feel natural rather than firm or displaced.

The 0.3% lidocaine is co-formulated directly into the gel, reducing injection discomfort during administration in the perioral region without requiring a separate anesthetic step. Co-formulated mannitol acts as a potent free-radical scavenger, neutralizing localized oxidative stress triggered by injection trauma to minimize initial post-treatment swelling. Topical anesthetic remains an option at the practitioner’s discretion.

About STYLAGE® LIPS PLUS BI-FLEX® with Lidocaine

STYLAGE® LIPS PLUS BI-FLEX® with Lidocaine is a dedicated lips filler from Laboratories VIVACY, CE-marked for professional aesthetic use in the EU. Within the STYLAGE® dermal filler range, the LIPS PLUS designation marks the higher-concentration lip option: 20mg/mL HA versus the lower 18.5mg/mL concentration of standard STYLAGE® Special Lips. This makes it the more appropriate choice when the clinical goal is pronounced augmentation or correction of significant volume loss.

Practitioners evaluating whether STYLAGE® is a good filler for lip indications will find the answer largely in its formulation choices:

• IPN-Like Technology™ maintains structural integrity across the full range of lip movement.
• Lip-optimized rheology is calibrated specifically for dynamic mucosal tissue, not adapted from a mid-face or skin-booster formula.
• Mannitol stabilization shields the matrix from early free-radical degradation.
• Lidocaine is built in at 0.3%, which improves tolerability in this sensitive treatment area.

As a CE-marked product from an established French manufacturer, it meets the traceability and quality standards practitioners expect from professional-grade injectable dermal fillers.

When buying online, verifying local approval is a necessary first step. Those interested in wholesale arrangements for STYLAGE® LIPS PLUS BI-FLEX® with Lidocaine should contact Medica Depot’s support representatives for sourcing information and documentation support.

Indications & Clinical Use

STYLAGE® LIPS PLUS BI-FLEX® with Lidocaine is indicated for lip augmentation, perioral volume restoration, and correction of volume loss in the lips treatment area. Specific applications include volumizing the lip body, defining the vermillion border, enhancing the philtrum columns, and treating superficial perioral lines. These are all within the scope of aesthetic medicine practice for licensed professionals.

The 20mg/mL concentration suits patients seeking pronounced augmentation or those with a more significant baseline volume deficit. Before treatment, practitioners should assess factors such as skin type, mucosal tissue quality, and the intended aesthetic outcome. The product is contraindicated in patients with known hypersensitivity to HA, mannitol, or amide-type anesthetics.

Standard precautions apply: aseptic technique throughout, intravascular injection avoided, and a full contraindication screen completed prior to any STYLAGE® LIPS PLUS BI-FLEX® with Lidocaine injection. Refer to the IFU for complete clinical guidance.

STYLAGE® LIPS PLUS BI-FLEX® with Lidocaine Injection: Administration, Side Effects & Safety

Injection may be performed into the lip body, along the vermillion border, or into the philtrum columns, with technique and volume left to practitioner judgment based on individual patient anatomy. The co-formulated lidocaine reduces discomfort at the injection site; a supplemental topical anesthetic can be added if preferred.

Post-treatment, patients should be advised to avoid sun exposure until redness and swelling resolve. Patients should also avoid strenuous physical activity, alcohol, and facial heat treatments in the immediate post-treatment period.

Common Adverse Effects

Common side effects include bruising at the injection site, swelling, redness, and tenderness. All are transient and localized to the lips treatment area. Most resolve within a few days and are consistent with what practitioners expect from injectable dermal fillers in this area.

Serious Adverse Events (Rare)

Serious adverse events are rare but include vascular occlusion, skin necrosis, and visual disturbance. Practitioners should be trained in managing vascular complications before treating the perioral region. Screen all patients for hypersensitivity to HA or amide-type anesthetics, and refer to the full IFU for complete safety data and management protocols.

Practitioners must consult the full Instructions for Use (IFU) provided with the product for the complete list of contraindications, warnings, precautions, and adverse event management protocols before administering STYLAGE® LIPS PLUS BI-FLEX® with Lidocaine.

Legal & Regulatory Status

STYLAGE® LIPS PLUS BI-FLEX® with Lidocaine is CE-marked and produced in France by Laboratories VIVACY for professional aesthetic use within the EU. It is not currently approved by the US FDA. Use is restricted to licensed medical professionals and registered aesthetic clinics operating within their applicable regulatory frameworks. Practitioners should independently verify local regulatory status before sourcing. Information on this page is current as of 2026.

Practitioners wishing to buy STYLAGE® or buy dermal fillers through an authorized channel should confirm product authenticity and documentation with their chosen distributor. For sourcing guidance, contact Medica Depot’s support representatives.

Citations

1. Kablik J, Monheit GD, Yu L, Chang G, Gershkovich J. Comparative physical properties of hyaluronic acid dermal fillers. Dermatol Surg. 2009;35(suppl 1):302-312. doi: 10.1111/j.1524-4725.2008.01046.x
2. Sundaram H, Cassuto D. Biophysical characteristics of hyaluronic acid soft-tissue fillers and their relevance to aesthetic applications. Plast Reconstr Surg. 2013;132(4 suppl 2):5S-21S. doi: 10.1097/PRS.0b013e31829c4edf
3. Stocks D, Sundaram H, Michaels J, Durrani MJ, Wortzman MS, Nelson DB. Rheological evaluation of the physical properties of hyaluronic acid dermal fillers. J Drugs Dermatol. 2011;10(9):974-980.

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.